PALI
NASDAQPalisade Bio Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.95-0.05 (-2.50%)
2026-03-192026-06-23
News · 26 weeks53+10%
2025-12-282026-06-21
Mix3090d
- SEC Filings10(33%)
- Other9(30%)
- Insider7(23%)
- Analyst2(7%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERDirector Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by new insider Baltera Robert Jr.3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Wei Binxian was granted 592,300 shares and converted options into 20,200 shares, increasing direct ownership by 71,637% to 613,355 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Williams Donald Allen converted options into 60,666 shares and was granted 1,498,900 shares, increasing direct ownership by 14,537% to 1,570,294 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Chuang Emil was granted 592,300 shares and converted options into 20,200 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Zwick Jordan Michael was granted 336,904 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zwick Jordan Michael3 - PALISADE BIO, INC. (0001357459) (Issuer)
- SECPalisade Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of DirectorsBoard strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors. "We are pleased to welcome both Robert and Jordan to the Palisade Bio Board
- SECSEC Form S-8 filed by Palisade Bio Inc.S-8 - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences SymposiumPresentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences ("NYAS") symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026, in New York, NY.
- PRPalisade Bio to Participate in the Jefferies Global Healthcare ConferenceManagement presentation to take place on Thursday, June 4th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York. The Company's presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM E
- SECSEC Form EFFECT filed by Palisade Bio Inc.EFFECT - PALISADE BIO, INC. (0001357459) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form SCHEDULE 13G filed by Palisade Bio Inc.SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form S-3 filed by Palisade Bio Inc.S-3 - PALISADE BIO, INC. (0001357459) (Filer)
- SECPalisade Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead progra
- SECSEC Form 10-Q filed by Palisade Bio Inc.10-Q - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisData demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval Steady-state pharmacokinetic findings provide mechanistic support for previously reported Phase 1b clinical activity Additional findings support PALI-2108's potential as a once-daily, gut-targeted oral therapy Data presented at Digestive Disease Week 2026 – Access the Poster Here Denver, CO, May 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum a
- SECSEC Form DEFA14A filed by Palisade Bio Inc.DEFA14A - PALISADE BIO, INC. (0001357459) (Filer)
- SECSEC Form DEF 14A filed by Palisade Bio Inc.DEF 14A - PALISADE BIO, INC. (0001357459) (Filer)
- SECSEC Form PRE 14A filed by Palisade Bio Inc.PRE 14A - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago. The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory
PALI FAQ
6 questionsWhat does Palisade Bio Inc. do?
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad...Where does PALI stock trade?
Palisade Bio Inc. (PALI) is listed on NASDAQ.What sector and industry is PALI in?
Palisade Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about PALI?
Palisade Bio Inc. has had 7 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $700.00 price target on 2026-04-09. Recent price targets range from $500.00 to $2500.00.What companies are similar to PALI?
Notable peers in the same industry include CABA (Cabaletta Bio Inc.), GRPH (Graphite Bio Inc.), ACET (Adicet Bio Inc.), TIL (Instil Bio Inc.), INMB (INmune Bio Inc.). Compare PALI side-by-side with any of them on Quantisnow.How can I track PALI on Quantisnow?
Quantisnow aggregates Palisade Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PALI to receive live email and push alerts on every new disclosure.